- Home
- VVV vs OGN Comparison
VVV vs OGN Comparison
Compare VVV & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VVV
- OGN
- Stock Information
- Founded
- VVV 1866
- OGN 1923
- Country
- VVV United States
- OGN United States
- Employees
- VVV N/A
- OGN N/A
- Industry
- VVV Major Chemicals
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- VVV Industrials
- OGN Health Care
- Exchange
- VVV Nasdaq
- OGN Nasdaq
- Market Cap
- VVV 4.7B
- OGN 4.0B
- IPO Year
- VVV 2016
- OGN N/A
- Fundamental
- Price
- VVV $34.82
- OGN $14.89
- Analyst Decision
- VVV Buy
- OGN Hold
- Analyst Count
- VVV 10
- OGN 5
- Target Price
- VVV $44.40
- OGN $20.80
- AVG Volume (30 Days)
- VVV 1.5M
- OGN 3.9M
- Earning Date
- VVV 05-07-2025
- OGN 05-01-2025
- Dividend Yield
- VVV N/A
- OGN 7.52%
- EPS Growth
- VVV N/A
- OGN N/A
- EPS
- VVV 2.08
- OGN 3.33
- Revenue
- VVV $1,659,900,000.00
- OGN $6,403,000,000.00
- Revenue This Year
- VVV $8.89
- OGN N/A
- Revenue Next Year
- VVV $14.18
- OGN $0.71
- P/E Ratio
- VVV $16.81
- OGN $4.47
- Revenue Growth
- VVV 11.85
- OGN 2.23
- 52 Week Low
- VVV $33.90
- OGN $13.87
- 52 Week High
- VVV $48.27
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- VVV 41.87
- OGN 46.51
- Support Level
- VVV $34.44
- OGN $14.81
- Resistance Level
- VVV $35.54
- OGN $14.81
- Average True Range (ATR)
- VVV 0.81
- OGN 0.48
- MACD
- VVV 0.02
- OGN -0.07
- Stochastic Oscillator
- VVV 25.80
- OGN 36.66
About VVV Valvoline Inc.
Valvoline Inc produces, markets, and sells automotive maintenance products, particularly lubricants, to retail outlets installers, and customers. The company offers various products such as engine oil, heavy-duty engine oil, motorcycle oil, grease and brake fluid, and others. Geographically, the majority of the revenue is generated from the United States of America.
About OGN Organon & Co.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.